^ ab“Tagrisso (osimertinib) Tablet, for Oral Use. Full Prescribing Information”. AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850. 2015年11月16日閲覧。
^“Proposed INN: List 113”. International Nonproprietary Names for Pharmaceutical Substances (INN)29 (2): 285. (2015). http://www.who.int/medicines/publications/druginformation/INN_List113.pdf2015年11月16日閲覧。.
^Ayeni D, Politi K, Goldberg SB (2015). “Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer”. Clin. Cancer Res.21 (17): 3818–20. doi:10.1158/1078-0432.CCR-15-1211. PMID 26169963.
^Tan CS, Gilligan D, Pacey S (2015). “Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer”. Lancet Oncol.16 (9): e447–59. doi:10.1016/S1470-2045(15)00246-6. PMID 26370354.
^U.S. Food and Drug Administration. Hematology/Oncology (Cancer) Approvals & Safety Notifications. [1]
^Xu M, Xie Y, Ni S, Liu H (2015). “The latest therapeutic strategies after resistance to first generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients with non-small cell lung cancer (NSCLC)”. Ann Transl Med3 (7): 96. doi:10.3978/j.issn.2305-5839.2015.03.60. PMC: 4430733. PMID 26015938. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4430733/.
^U.S. Food and Drug Administration. "Osimertinib". [2]
^Tagrisso (osimertinib) approved in EU as first-in-class treatment for patients with EGFR T790M mutation-positive metastatic non-small cell lung cancer
…improved outcomes with front-line treatment with the third-generation agent, osimertinib. Given these data, we prefer osimertinib as the front-line treatment option, although earlier-generation EGFR TKIs …
…activity seen thus far with osimertinib. Studies comparing osimertinib with local therapies for the management of brain metastases are lacking; however, clinical data with osimertinib reveal encouraging activity …
…treated with osimertinib after an anti-PD-1 agent developed ILD (42.8 percent), whereas treatment with a first- or second-generation agent after treatment with an anti-PD-1 agent, or with osimertinib before …
…retention occurs with bosutinib and may manifest as pericardial effusion or pulmonary edema . Osimertinib is active in non-small cell lung cancers harboring the EGFR T790M mutation. Given a small risk …
…(EGFR) tyrosine kinase inhibitors – The EGFR tyrosine kinase inhibitors erlotinib, gefitinib, and osimertinib have activity in patients with non-small cell lung cancer (NSCLC). This activity is most evident …